Biogen stock falls after FDA calls for federal investigation into Alzheimer’s drug approval
Biogen shares fell Friday after the head of the FDA called for an investigation into the recent approval of the company’s Alzheimer’s drug, Aduhelm.
—————
TRANSCOM ISP – Free Sigma HSE Email
Level 6 Domain Names are FREE – Register Now.
